The US Supreme Court has denied certiorari for the generic version of Tamiflu (Oseltamivir Phosphate) oral capsules. It is indicated for treatment of influenza.
The development saw the company’s scrip gaining 5.81 per cent to close the day at Rs. 1,642.80 on the BSE.
Hyderabad-based Natco Pharma partners with Alvogen for marketing of this product in the US.
The denial was issued on Monday in the case of Gilead Sciences Inc, Natco informed the BSE on Tuesday.
Certiorari is a writ seeking judicial review. It is issued by a superior court, directing an inferior court, tribunal or other public authority to send the record of a proceeding for review.
Pearson Syndrome is an extremely rare condition and the prevalence is approximately 1 in a…
A striking 90% of the 3000 Diabetologists and Endocrinologists surveyed, emphasised the importance of continuous…
People who smoke are also at much higher risk of developing diabetes compared to non-smokers…
17th edition of CPHI& PMEC India Expo to be held from 26th November-28thNovember 2024, at the India…
Lonavala, November 12, 2024: As the global cancer burden rises to 30 million cases by…
The launch signifies Equitas’ redefined commitment to bring world-class cancer radiation therapy accessible to all.…